🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥 HARMONi-2: Ivonescimabe x Pembro - 1L mCPNPC PD-L1+ 📌 Fase 3, randomizado (NCT05499390) 💉 Mab biespecífico anti-PD1/ anti-VEGF 🔹️Análise interina: 📈 SLP: 11,1 x 5,8 m (HR 0,51; p<0,0001) Benefício: TPS 1–49% e ≥50% ⚠️ EA G3+: 29 (ivo) x 16% (pembro) 🆕 Futura opção 1L?

Estudo multicênt. retrospectivo 🇰🇷: AdenoCA EC I–III EGFR mut. N= 759 Taxa recorrência global 39,1% Sobrevida livre de recorrência: 59,8m. Fatores de risco: idade ≥65a, IMC <18,5 kg/m², subtipo Del19, T ≥2,3 cm, N1 e N2, padrão micropapilar ou sólido e inv. visceral pleural.

ACS Journal Cancer📰: Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive #BreastCancer in the Surveillance, Epidemiology, and End Results database, 2010-2019. 🔓pubmed.ncbi.nlm.nih.gov/39887682/ ✍️Ada Waks Paolo Tarantino Nancy Lin, MD Nabihah Tayob

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients dlvr.it/TJZrTP

🚨🔥OncoAlert Hot off the press Just published Nature Medicine Results of longitudinal analysis of #Molecular #Residual #Disease (#MRD) from #ADAURA phase 3 trial of adjuvant #Osimertinib in resected #EGFR+ stage IB–IIIA non-small-cell #LungCancer 👇🏻 nature.com/articles/s4159…

🔥 Nature Medicine 🆙 ✅A B7H3-targeting antibody–drug conjugate (YL201) in advanced solid tumors: a phase 1/1b trial 🎯ORR ES-SCLC 63.9%, lung adenocarcinoma 28.6%, and lymphoepithelioma-like carcinoma 54.2% 👥Dr. Yuxiang Ma #LCSM OncoAlert #ADC nature.com/articles/s4159…

Volcano snails, or Alviniconcha, live deep in the ocean near hot vents where water can reach 750°F (400°C). They survive by feeding on chemicals like sulfur and methane. Their shells are rich in iron, bearing extreme heat and pressure. [🎞️ Earth 2.0]

I'm so happy to see this project about sexual dysfunction in men moving forward! The abstract has been accepted for ASCO 2025. Teamwork rewarded ! Vladmir C. Cordeiro de Lima, MD, PhD Aldo L. A. DETTINO Gil-Santana

Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront? Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami. Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25

We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks ➕promising than chemo+Amiv. Better 🧠 protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT? #ELCC25

⚠️GBOT no ELCC: SAVANNAH: fase 2 - pts CPNPC EGFRmut pós PD a Osimertinibe c/ hiperexpressão e/ou amplificação de MET ➡️ Savolitinib + Osi N=80 ORR:56% PFS: 7,5m EA ≥G3: 57% Potencial tratamento para esses pacientes! Estudo fase 3 em andamento no Brasil 🇧🇷

SOHO-01: Fase I/II ➡️BAY 2927088 (TKI) em CPNPC HER2 mut. coorte D (virgens dentro.) e coorte E (prev. tratados c/ ADC). coorte D: ORR 70,5%; mDoR 8,7m coorte E: ORR 35,3%; mDoR 9,5m EA: diarreia, rash, náusea e paroníquia 🚫Doença Intersticial Pulmonar. Fase III em andamento!

⚠️GBOT no ELCC ❗️Estudo ORCHARD 🎯CPNPC EIV EGFRm 2L (pós Osi) 🔍Osi+ Dato-DXd (4mg/kg x 6mg/kg) Fase 2 ✅️ mPFS favoreceu 6mg/kg (11,7x 9,5m) ✅️ %ORR similar (43 x 36) ⬆️EAs na coorte 6mg/kg (mucosite, eventos oculares, pneumonite).

⚠️GBOT no ELCC COCOON: Fase 2 - tto. dermatológico profilático (DM) vs. tto. padrão de toxicidade (SC) em CPCNP EGFRmut c/ AMI + LAZER N=138 12ºsem: EA ≥2 39% x 76% (DM x SC) EA G3: 4% x 9% (DM x SC) ⬇️ Descontinuação: 11% x 19% ✅ Melhora no manejo dos efeitos adervsos!

⚠️GBOT no ELCC MK-3475A-D77: Pembro 790mg SC q6w vs. Pembro 400mg IV q6w (+ QT ) em CPNPC sem mutação driver 1L N=377 ORR: 45,4% X 42,1% (SC x IV) PFS: 8,1 X 7,8m (SC x IV) OS: NR EA ≥G3: 47,0% X 47,6% (SC x IV) Pembro SC com exposição e concentração não-inferior a Pembro IV👏🏻

⚠️GBOT no ELCC BO44178: Fase 2, randomizado: CPNPC 1L sem driver ➡️ QT + Tobemstomig (anti-PD-1 e anti-LAG-3) ❌ QT + Pembro ORR: 41% X 46% (tobe x pembro) PFS: 7,6 X 7,1m (HR: 0,99) (tobe x pembro) >EA G3/4: 66% X 50% (tobe x pembro). Dados não muito animadores…

⚠️GBOT no ELCC KRYSTAL-7: Adagrasib + Pembro em CPNPC KRAS G12C e PD-L1 > 50%. ✅ORR: 59% ✅DCR: 81% ✅mDOR: 26,3m ✅PFS: 27,7m ✅OS: NR Perfil de toxicidade compatível (3 G5❗️) Ph3 em andamento!

⚠️ GBOT no ELCC ❗️KROCUS: Ph2 - CPNPC KRAS G12C 1L: Fulzerasib (KRAS G12C) + Cetuximab (EGFR) ORR: 80% 👏🏻 mDoR: NR PFS: 12,5m OS: NR Analise preliminar com eficácia em Meta cerebral 👍🏻 EA: rash (53,2%), prurido, astenia e náusea Ph3 em planejamento!

#ELCC25 Mini Orals Ph II AMAZE-Lung Trial: 2L ami-laz-bev post 3rd gen TKI by #RossSoo ETOP IBCSG Partners Foundation: - 61pts - ORR at 12wks 33% - mDOR 13.9m, mPFS 10.9m, mOS 15.5m An example of targeting VEGF in EGFR+ NSCLC, &another chemo-free approach ESMO - Eur. Oncology EGFR Resisters OncoAlert #LCSM

Sadly, I decided leaving X. Unfortunately, this app serves someone who has no respect or consideration for other people's lives, and cares only about his money and power.